Magnesium supplements treatment with methylphenidate in children with attention-deficit/hyperactivity disorder

Effect of magnesium supplements as complementary treatment with methylphenidate in children with attention-deficit/hyperactivity disorder

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016062518927N4

Enrollment

Registered

2017-09-30

Start date

2017-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit hyperactivity disorder (ADHD). Disturbance of activity and attention

Interventions

Intervention 1: In intervention group: Patients will receive 0.5 to 1 mg/kg/day methylphenidate tablet with 10 mg/daily magnesium tablets for 8 weeks. Intervention 2: In control group: Patients will r

Treatment - Drugs

In intervention group: Patients will receive 0.5 to 1 mg/kg/day methylphenidate tablet with 10 mg/daily magnesium tablets for 8 weeks.

In control group: Patients will receive 0.5 to 1 mg/kg/day methylphenidate tablet with placebo for 8 weeks.

Eligibility

Sex/Gender

All

Age

7 Years to 12 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: children between 7-12 aged; ADHD diagnosis by expert pediatric psychology physician using DSM diagnosis index; No prevention for Magnesium supplements; IQ index above 70; Without other psychology disorders; No intake of Magnesium supplements since 2 months ago; Intake of methylphenidate tablet with a dose of 0.5-1 mg/kg/day as a medical treatment. Exclusion criteria:Stop the treatment by the child or parents; incorrect intake of the drug by the child; change the treatment method; Stop the treatment due to the side effects of the drug; Acute physical disease.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Change in score of Conners' Parent Questionnaire. Timepoint: Beginig of study and 8 weeks later. Method of measurement: Conners' Parent Questionnaire.	—

Secondary

Measure	Time frame
Adverse effects. Timepoint: 8 weeks later. Method of measurement: Patient follow up.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Seyed Gholamreza Noorazar

Tabriz University of Medical Sciences.

noorazars@tbzmed.ac.ir+98 41 3380 3353

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026